22nd Apr 2016 09:53
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR AN INVITATION TO ACQUIRE OR DISPOSE OF ANY SECURITIES.
22 April 2016
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Completion of Acquisition of Putney, Inc.
Further to the announcement on 15 April 2016, Dechra is pleased to announce that the acquisition of Putney, Inc. has now completed.
Further details on the integration will be given at the Company's next trading update in July.
Enquiries:
Dechra Pharmaceuticals PLC | |
Ian Page, Chief Executive Officer Anne-Francoise Nesmes, Chief Financial Officer | Office: +44 (0)1606 814730 Email: [email protected] |
Investec | |
Chris Treneman Daniel Adams Matt Lewis Jonathan Wynn | Tel: 020 7597 4000 |
TooleyStreet Communications Ltd | |
Fiona Tooley, Director | Mobile: +44 (0)7785 703 523 Email: [email protected] |
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Related Shares:
DPH.L